
Neurodegenerative collaboration seeks novel drug candidates
Neurimmune has signed an expanded drug discovery collaboration agreement with Ono Pharmaceutical, which is focused on creating antibody drugs against new therapeutic targets in the field of neurodegenerative diseases utilising Neurimmune’s proprietary Reverse Translational Medicine (RTM) technology platform, an antibody drug creation approach. Background In November 2017, Ono and Neurimmune signed… Read More













